Cargando…

Multi-therapeutic strategy targeting parasite and inflammation-related alterations to improve prognosis of chronic Chagas cardiomyopathy: a hypothesis-based approach(*)

Chagas disease (CD), caused by infection by the protozoan parasite Trypanosoma cruzi, presents as main clinical manifestation the chronic chagasic cardiomyopathy (CCC). CCC afflicts millions of people, mostly in Latin America, and vaccine and effective therapy are still lacking. Comprehension of the...

Descripción completa

Detalles Bibliográficos
Autor principal:	Lannes-Vieira, Joseli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Instituto Oswaldo Cruz, Ministério da Saúde 2022
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944190/ https://www.ncbi.nlm.nih.gov/pubmed/35320825 http://dx.doi.org/10.1590/0074-02760220019

Ejemplares similares

Anxiety, depression, and memory loss in Chagas disease: a puzzle far beyond neuroinflammation to be unpicked and solved(*)
por: Lannes-Vieira, Joseli, et al.
Publicado: (2023)

Behavioural alterations are independent of sickness behaviour in chronic experimental Chagas disease
por: Vilar-Pereira, Glaucia, et al.
Publicado: (2015)

Treatment With Suboptimal Dose of Benznidazole Mitigates Immune Response Molecular Pathways in Mice With Chronic Chagas Cardiomyopathy
por: Farani, Priscila Silva Grijó, et al.
Publicado: (2021)

Tumor Necrosis Factor Is a Therapeutic Target for Immunological Unbalance and Cardiac Abnormalities in Chronic Experimental Chagas' Heart Disease
por: Pereira, Isabela Resende, et al.
Publicado: (2014)

The Centennial of the Discovery of Chagas Disease: Facing the Current Challenges
por: Lannes-Vieira, Joseli, et al.
Publicado: (2010)

Severity of chronic experimental Chagas' heart disease parallels tumour necrosis factor and nitric oxide levels in the serum: models of mild and severe disease
por: Pereira, Isabela Resende, et al.
Publicado: (2014)

Treatment with benznidazole and pentoxifylline regulates microRNA transcriptomic profile in a murine model of Chagas chronic cardiomyopathy
por: Silva Grijó Farani, Priscila, et al.
Publicado: (2023)

Memory impairment in chronic experimental Chagas disease: Benznidazole therapy reversed cognitive deficit in association with reduction of parasite load and oxidative stress in the nervous tissue
por: Vilar-Pereira, Glaucia, et al.
Publicado: (2021)

Vascular Growth Factor Inhibition with Bevacizumab Improves Cardiac Electrical Alterations and Fibrosis in Experimental Acute Chagas Disease
por: Nisimura, Lindice Mitie, et al.
Publicado: (2023)

Chronic Chagas cardiomyopathy
por: Aiello, Vera Demarchi, et al.
Publicado: (2015)

Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial
por: Rassi, Anis, et al.
Publicado: (2017)

Extracellular Vesicles: Potential Role in Remote Signaling and Inflammation in Trypanosoma cruzi-Triggered Disease
por: Dantas-Pereira, Luíza, et al.
Publicado: (2021)

Parasitic Load Correlates With Left Ventricular Dysfunction in Patients With Chronic Chagas Cardiomyopathy
por: de Oliveira, Maykon Tavares, et al.
Publicado: (2021)

Transforming growth factor-ß as a therapeutic target for the cardiac damage of Chagas disease
por: Waghabi, Mariana Caldas, et al.
Publicado: (2022)

Biomakers in Chronic Chagas Cardiomyopathy
por: Rodrigues, Angela Braga, et al.
Publicado: (2022)

Pathogenesis of Chagas Cardiomyopathy: Role of Inflammation and Oxidative Stress
por: Machado, Fabiana S., et al.
Publicado: (2013)

Combination Chemotherapy with Suboptimal Doses of Benznidazole and Pentoxifylline Sustains Partial Reversion of Experimental Chagas' Heart Disease
por: Vilar-Pereira, Glaucia, et al.
Publicado: (2016)

Cognitive dysfunction in chronic Chagas disease cardiomyopathy
por: Dias, Jesângeli Sousa, et al.
Publicado: (2009)

Genetic Ablation and Pharmacological Blockade of Bradykinin B1 Receptor Unveiled a Detrimental Role for the Kinin System in Chagas Disease Cardiomyopathy
por: Oliveira, Ana Carolina, et al.
Publicado: (2023)

CCL3/Macrophage Inflammatory Protein-1α Is Dually Involved in Parasite Persistence and Induction of a TNF- and IFNγ-Enriched Inflammatory Milieu in Trypanosoma cruzi-Induced Chronic Cardiomyopathy
por: Gibaldi, Daniel, et al.
Publicado: (2020)

A Human Type 5 Adenovirus-Based Trypanosoma cruzi Therapeutic Vaccine Re-programs Immune Response and Reverses Chronic Cardiomyopathy
por: Pereira, Isabela Resende, et al.
Publicado: (2015)

Treatment of Chagas Cardiomyopathy
por: Botoni, Fernando A., et al.
Publicado: (2013)

Diet Alters Serum Metabolomic Profiling in the Mouse Model of Chronic Chagas Cardiomyopathy
por: Lizardo, Kezia, et al.
Publicado: (2019)

Pentoxifylline Reverses Chronic Experimental Chagasic Cardiomyopathy in Association with Repositioning of Abnormal CD8(+) T-Cell Response
por: Pereira, Isabela Resende, et al.
Publicado: (2015)

Resveratrol Reverses Functional Chagas Heart Disease in Mice
por: Vilar-Pereira, Glaucia, et al.
Publicado: (2016)

Chagas Cardiomyopathy in the Context of the Chronic Disease Transition
por: Hidron, Alicia I., et al.
Publicado: (2010)

Perspectives for a new drug candidate for Chagas disease therapy
por: Soeiro, Maria de Nazaré Correia
Publicado: (2022)

Call for Consensus in the Evaluation of Circulating Matrix Metalloproteinases in Chagas Disease
por: Bautista-López, Norma L., et al.
Publicado: (2022)

Clinical Presentations of Chagas Cardiomyopathy
por: Shehadeh, Malik, et al.
Publicado: (2020)

Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis
por: Lecca, Daniela, et al.
Publicado: (2022)

Physical Exercise Promotes a Reduction in Cardiac Fibrosis in the Chronic Indeterminate Form of Experimental Chagas Disease
por: Pedra-Rezende, Yasmin, et al.
Publicado: (2021)

Genetic Polymorphism at CCL5 Is Associated With Protection in Chagas’ Heart Disease: Antagonistic Participation of CCR1(+) and CCR5(+) Cells in Chronic Chagasic Cardiomyopathy
por: Batista, Angelica Martins, et al.
Publicado: (2018)

Sulfadiazine Plus Pyrimethamine Therapy Reversed Multiple Behavioral and Neurocognitive Changes in Long-Term Chronic Toxoplasmosis by Reducing Brain Cyst Load and Inflammation-Related Alterations
por: Castaño, Barrios Leda, et al.
Publicado: (2022)

Genomic surveillance: a potential shortcut for effective Chagas disease management
por: de Azevedo, Sophia Lincoln Cardoso, et al.
Publicado: (2023)

Regulation of mammalian target of rapamycin on ferroptosis: from mechanism to therapeutics in septic cardiomyopathy
por: Zhao, Guoyu, et al.
Publicado: (2022)

Modulation of miR-145-5p and miR-146b-5p levels is linked to reduced parasite load in H9C2 Trypanosoma cruzi infected cardiomyoblasts
por: Farani, Priscila Silva Grijó, et al.
Publicado: (2022)

The oxidative damage initiation hypothesis for meiosis
por: Hörandl, Elvira, et al.
Publicado: (2013)

Antioxidant defence system as a rational target for Chagas disease and Leishmaniasis chemotherapy
por: Santi, Ana Maria Murta, et al.
Publicado: (2022)

Advanced management of ventricular arrhythmias in chronic Chagas cardiomyopathy
por: Santacruz, David, et al.
Publicado: (2021)

Chronic lung disease, lung regeneration and future therapeutic strategies
por: Cao, Xuan-Ye, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_giu7vdicpatc3ncl8cjdi3jrp5